Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 31, 2026, 10:26 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 337–360 of 1,787 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Intervention 2 - Sham Treatment Clear all
Completed Phase 2 Interventional Results available

Treatment for Calcium Phosphate Kidney Stone Disease

NCT01754779
View directory record Official record
Conditions
Calcium Phosphate Kidney Stones
Interventions
Placebo, Citric Acid, Potassium Citrate
Dietary Supplement
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
21 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2023
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Apr 4, 2024 · Synced Oct 31, 2026, 10:26 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

The Effect of AMP Human Sodium Bicarbonate Lotion on Dehydrated Heat Stress

NCT05092854
View directory record Official record
Conditions
Fluid Retention, Sodium Retention, Heat Stress, Dehydration (Physiology), Renal Injury, Electrolyte and Fluid Balance Conditions
Interventions
PR Lotion - AMP Human Performance, Placebo Lotion, AminoVital - Rapid Recovery, Placebo Supplement
Other
Lead sponsor
University of Connecticut
Other
Eligibility
18 Years to 45 Years · Male only
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Storrs, Connecticut
Source: ClinicalTrials.gov public record
Updated Oct 24, 2022 · Synced Oct 31, 2026, 10:26 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Poke and a Placebo

NCT04497220
View directory record Official record
Conditions
Anesthesia
Interventions
Negative Connotation Langauge, Positive Connotation Language
Behavioral
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years and older · Female only
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2026
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Jan 8, 2026 · Synced Oct 31, 2026, 10:26 AM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Treatment of Asian Flushing Syndrome With Topical Alpha Agonists

NCT03497442
View directory record Official record
Conditions
Flushing, Alcohol-Related Disorders, Aldehyde Dehydrogenase Deficiency
Interventions
Brimonidine Tartrate, Placebo Vehicle Gel
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
21 Years and older
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated May 4, 2020 · Synced Oct 31, 2026, 10:26 AM EDT
Completed Early Phase 1 Interventional

A Novel Brain Stimulation for Bimanual Motor Function and Control in Chronic Stroke

NCT05381740
View directory record Official record
Conditions
Stroke
Interventions
Novel rTMS Approach, Sham rTMS Approach
Device
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years to 90 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 3, 2024 · Synced Oct 31, 2026, 10:26 AM EDT
Active, not recruiting Phase 2 Interventional Results available

Investigation of Metformin for the Prevention of Progression of Precursor Multiple Myeloma

NCT04850846
View directory record Official record
Conditions
Monoclonal Gammopathy of Undetermined Significance, Smoldering Multiple Myeloma
Interventions
Metformin XR, Placebo
Drug · Other
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
7
States / cities
Boston, Massachusetts • Brighton, Massachusetts • Methuen, Massachusetts + 3 more
Source: ClinicalTrials.gov public record
Updated Feb 9, 2026 · Synced Oct 31, 2026, 10:26 AM EDT
Completed Phase 2 Interventional Results available

OIT and Xolair® (Omalizumab) in Cow's Milk Allergy

NCT01157117
View directory record Official record
Conditions
Milk Allergy
Interventions
Placebo for omalizumab, Omalizumab, Milk powder
Biological · Drug
Lead sponsor
Hugh A Sampson, MD
Other
Eligibility
7 Years to 35 Years
Enrollment
77 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
3
States / cities
Stanford, California • Baltimore, Maryland • New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 14, 2020 · Synced Oct 31, 2026, 10:26 AM EDT
Completed Not applicable Interventional Results available

The Effects of Respiratory Training on Voice

NCT04710862
View directory record Official record
Conditions
Muscle Tension Dysphonia
Interventions
Breathing training without a device, Breathing training with a device
Behavioral
Lead sponsor
Syracuse University
Other
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Syracuse, New York
Source: ClinicalTrials.gov public record
Updated Jul 24, 2025 · Synced Oct 31, 2026, 10:26 AM EDT
Recruiting Phase 2 Interventional

Interventional Study of Infigratinib in Children < 3 Years Old With Achondroplasia (ACH)

NCT07169279
View directory record Official record
Conditions
Achondroplasia
Interventions
Infigratinib is provided as a single dose of minitablets for oral administration, Infigratinib is provided as sprinkle capsules for daily oral administration, Infigratinib or placebo comparator is provided as sprinkle capsules for daily oral administration
Drug
Lead sponsor
QED Therapeutics, a BridgeBio company
Industry
Eligibility
0 Years to 32 Months
Enrollment
77 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2032
U.S. locations
3
States / cities
Oakland, California • Baltimore, Maryland • Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jul 13, 2026 · Synced Oct 31, 2026, 10:26 AM EDT
Completed Phase 2 Interventional Results available

Phase 2 Pilot Safety Study of MDMA-assisted Therapy for Social Anxiety in Autistic Adults

NCT02008396
View directory record Official record
Conditions
Social Anxiety in Autistic Adults
Interventions
Placebo, Midomafetamine HCl, Therapy
Drug · Behavioral
Lead sponsor
Resilient Pharmaceuticals
Industry
Eligibility
21 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Torrance, California
Source: ClinicalTrials.gov public record
Updated Jun 5, 2025 · Synced Oct 31, 2026, 10:26 AM EDT
Completed Phase 3 Interventional

Perioperative Pembrolizumab (MK-3475) Plus Neoadjuvant Chemotherapy Versus Perioperative Placebo Plus Neoadjuvant Chemotherapy for Cisplatin-eligible Muscle-invasive Bladder Cancer (MIBC) (MK-3475-866/KEYNOTE-866)

NCT03924856
View directory record Official record
Conditions
Bladder Cancer
Interventions
Pembrolizumab, Gemcitabine, Cisplatin, Surgery (radical cystectomy (RC) plus Pelvic Lymph Node Dissection [PLND]), Placebo
Drug · Procedure
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
907 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
24
States / cities
La Jolla, California • Santa Monica, California • Washington D.C., District of Columbia + 21 more
Source: ClinicalTrials.gov public record
Updated Oct 8, 2026 · Synced Oct 31, 2026, 10:26 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional Accepts healthy volunteers

Treatment of Orthostatic Intolerance

NCT00262470
View directory record Official record
Conditions
Tachycardia, Chronic Orthostatic Intolerance
Interventions
Acetazolamide, Atomoxetine, NO Drug, Clonidine, Entacapone, Entacapone & Propranolol, Atomoxetine & Propranolol, Indomethacin, Mecamylamine, Isosorbide Dinitrate, Melatonin, Midodrine, Modafinil, Octreotide, Placebo, Propranolol, Modafinil & Propranolol, Sertraline, IV Saline, Drinking Water, Breathing Device, memantine, Abdominal binder
Drug · Other · Dietary Supplement + 3 more
Lead sponsor
Satish R. Raj
Other
Eligibility
18 Years to 70 Years
Enrollment
150 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1997 – 2029
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Oct 16, 2026 · Synced Oct 31, 2026, 10:26 AM EDT
Completed Phase 2 Interventional Results available

Study to Assess Safety and Efficacy of Filgotinib, Lanraplenib and Tirabrutinib in Adults With Active Sjogren's Syndrome

NCT03100942
View directory record Official record
Conditions
Sjogren's Syndrome
Interventions
Lanraplenib, Filgotinib, Tirabrutinib, Lanraplenib placebo, Filgotinib placebo, Tirabrutinib placebo
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years to 75 Years
Enrollment
152 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
34
States / cities
Mesa, Arizona • Phoenix, Arizona • Covina, California + 31 more
Source: ClinicalTrials.gov public record
Updated Oct 23, 2020 · Synced Oct 31, 2026, 10:26 AM EDT
Not yet recruiting Early Phase 1 Interventional

Individualized fMRI-guided TMS for Depression

NCT07804459
View directory record Official record
Conditions
Depression, Major Depressive Disorder (MDD), Depression - Major Depressive Disorder, Persistent Depressive Disorder, PDD, MDD
Interventions
Active Repetitive Transcranial Magnetic Stimulation (rTMS), Sham Transcranial Magnetic Stimulation (TMS)
Device
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 65 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 9, 2026 · Synced Oct 31, 2026, 10:26 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Diet and Exercise Plus Metformin to Treat Frailty in Obese Seniors

NCT04221750
View directory record Official record
Conditions
Frailty, Sarcopenic Obesity, Aging
Interventions
Lifestyle therapy, Metformin Hydrochloride, Placebo, Healthy Lifestyle
Behavioral · Drug
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
65 Years to 85 Years
Enrollment
114 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2025
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 14, 2026 · Synced Oct 31, 2026, 10:26 AM EDT
Terminated Phase 2 Interventional Accepts healthy volunteers Results available

Eye Tracking as a Biomarker of Cannabis Effects

NCT04100590
View directory record Official record
Conditions
Cannabis Use, Pain, Acute
Interventions
Cannabis
Drug
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
21 Years to 55 Years
Enrollment
1 participant
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 30, 2022 · Synced Oct 31, 2026, 10:26 AM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Study of Changes in Total Cholesterol Levels as a Function of Consuming a Supplement Designed to Improve Cardiovascular Health

NCT01890889
View directory record Official record
Conditions
Cholesterol, Hyperlipidemia, Hypercholesteremia
Interventions
Ad-Chol-Pre, Half-dose Ad-Chol-Pre, Defatted egg yolk without the active ingredient of the other two interventions
Dietary Supplement · Other
Lead sponsor
Integrative Health Technologies, Inc.
Network
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Nov 25, 2013 · Synced Oct 31, 2026, 10:26 AM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

A Study to Investigate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD4248 in Healthy Participants and Participants With Chronic Kidney Disease and Type 2 Diabetes and to Assess Home Measurements of Creatinine in a Non Interventional Cohort

NCT07024823
View directory record Official record
Conditions
Chronic Kidney Disease
Interventions
AZD4248, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 75 Years
Enrollment
124 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
5
States / cities
Glendale, California • Chicago, Illinois • Ann Arbor, Michigan + 2 more
Source: ClinicalTrials.gov public record
Updated Aug 12, 2026 · Synced Oct 31, 2026, 10:26 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional Accepts healthy volunteers

Evaluation of D3 Receptor Occupancy Using FLUORTRIOPRIDE ([18F]FTP) PET/CT

NCT02815917
View directory record Official record
Conditions
D3 Dopamine Receptor, Cocaine-dependent, Healthy Volunteer
Interventions
[18F]FTP PET/CT
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 60 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2027
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 10, 2026 · Synced Oct 31, 2026, 10:26 AM EDT
Completed Phase 3 Interventional Results available

Study to Evaluate the Efficacy and Safety of Armodafinil Treatment (150 mg/Day) as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder

NCT01305408
View directory record Official record
Conditions
Depression
Interventions
Armodafinil, Placebo
Drug
Lead sponsor
Cephalon
Industry
Eligibility
18 Years to 65 Years
Enrollment
399 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
28
States / cities
Birmingham, Alabama • Sherman Oaks, California • Temecula, California + 21 more
Source: ClinicalTrials.gov public record
Updated May 26, 2016 · Synced Oct 31, 2026, 10:26 AM EDT
Completed Phase 3 Interventional

Efficacy and Safety APT-1011 in Adult Subjects With Eosinophilic Esophagitis (EoE) (FLUTE-2)

NCT04281108
View directory record Official record
Conditions
Eosinophilic Esophagitis
Interventions
APT-1011, Placebo oral tablet, Esophagogastroduodenoscopy
Drug · Procedure
Lead sponsor
Ellodi Pharmaceuticals, LP
Industry
Eligibility
18 Years and older
Enrollment
143 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
48
States / cities
Anniston, Alabama • Dothan, Alabama • Mobile, Alabama + 43 more
Source: ClinicalTrials.gov public record
Updated Jun 12, 2023 · Synced Oct 31, 2026, 10:26 AM EDT
Completed Not applicable Interventional

Project 4B: Lower Extremity Strength Training in ICU Patients

NCT02467023
View directory record Official record
Conditions
Sepsis
Interventions
Muscle stimulation with Niveus medical stimulator, measurement of maximal isometric twitch strength, Muscle Biopsy, Muscle Biopsy Medication: Lidocaine, Muscle Biopsy Medication: Versed, Muscle Biopsy Medication: Fentanyl, Blood and Urine Sampling, ineffective muscle stimulation
Device · Procedure · Drug + 1 more
Lead sponsor
University of Florida
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Jan 19, 2018 · Synced Oct 31, 2026, 10:26 AM EDT
Active, not recruiting Phase 4 Interventional

Effects of Sitagliptin in Individuals With Genetically Decreased DPP4

NCT04323189
View directory record Official record
Conditions
Genetics Disease, Type2 Diabetes, Heart Failure
Interventions
Sitagliptin 100mg, Placebo Oral Tablet
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 80 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 16, 2026 · Synced Oct 31, 2026, 10:26 AM EDT
Completed Phase 3 Interventional Results available

Comparison of Bimatoprost Sustained Release (SR) to Selective Laser Trabeculoplasty (SLT) in Adults With Open-Angle Glaucoma or Ocular Hypertension

NCT02507687
View directory record Official record
Conditions
Glaucoma, Open-Angle, Ocular Hypertension
Interventions
Bimatoprost SR, Sham Bimatoprost SR, Selective Laser Trabeculoplasty, Sham Selective Laser Trabeculoplasty
Drug · Procedure
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2023
U.S. locations
51
States / cities
Dothan, Alabama • Glendale, Arizona • Phoenix, Arizona + 43 more
Source: ClinicalTrials.gov public record
Updated May 10, 2024 · Synced Oct 31, 2026, 10:26 AM EDT